CHU Strasbourg - Hôpital de Hautepierre — Clinical Trial Site

8 Registered trials

6 Currently recruiting

Organisation

CHU Strasbourg - Hôpital de Hautepierre

Location

STRASBOURG, France

Identifier

ORL-000015459

Address

1 Avenue Molière, Service d'oncologie médicale, 67098, France

Departments

Medical Oncology
ONCOLOGIE MEDICALE
Oncologie médicale - Phase précoce
Service d'Onco-Hématologie Pédiatrique

Clinical trials at this site (8)

Search interface

CAALL-F01: a French protocol for the treatment of acute lymphoblastic leukemia (ALL) in children and adolescents Pending

2024-514243-29-01 This is a prospective, French, multicenter, open-label, 5
An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to ch… Recruiting

2024-516782-36-00 metastatic or recurrent endometrial or ovarian carcinos 4 2024-10-15
SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa… Recruiting

2023-508260-30-01 Patients with poor prognostic OVARian cancers based on 5 2024-07-30
ALEPRO: abemaciclib and letrozole in estrogen receptor positive rare ovarian cancer Recruiting

2023-503533-21-00 Low-grade serous ovarian cancer 4 2023-11-21
Phase 1/1b study to assess the drug OBT076 in patients with recurrent and/or metastatic CD205-positive solid tumors Recruiting

2024-511884-27-00 CD205+ve recurrent and/or metastatic tumor types includ 3 2022-11-09
Study of axitinib +/- pembrolizumab in first line treatment for patients with locally advanced or metastatic papillary renal cell carcinoma … Recruiting

2024-513986-38-00 Locally advanced or metastatic papillary cell carcinoma 4 2022-06-01
Multicentric non-randomized phase II of pembrolizumab in combination with etoposide-cisplatin-based chemotherapy in first-line small cell ov… Recruiting

2024-515310-40-01 Patients with a confirmed diagnosis of ovarian small ce 4 2021-08-04
Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc… Ended

2023-510097-14-00 Patients with MMR deficient relapse or advanced / metas 5 2022-04-15